文献速递脑血管病

去氨普酶治疗大动脉闭塞卒中3至9小时:DIAS-4试验

Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke).
PubMed 文献 · Stroke · 2016-11-01

DIAS-4试验因故提前终止,124例去氨普酶组中41.9%和128例安慰剂组中35.9%达到90天mRS 0-2分(OR 1.45,95%CI 0.79-2.64,P=0.23),安全性和死亡率无差异;汇总分析显示去氨普酶提高再通率但不显著改善功能结局。

要点

  • 去氨普酶90μg/kg在卒中后3-9小时使用安全,不增加症状性颅内出血和死亡。
  • 去氨普酶显著提高血管再通率(49.3% vs 38.3%),但90天功能结局无显著改善。
  • 再通与两治疗组90天良好功能结局均相关。

核心结论

  • 晚期(3-9小时)静脉给予90μg/kg去氨普酶安全,可提高动脉再通率,但未显著改善3个月功能结局。

研究设计与样本

  • DIAS-4为随机、安慰剂对照试验,纳入大动脉闭塞/重度狭窄的缺血性卒中患者,随机接受静脉去氨普酶90μg/kg或安慰剂。
  • 事后汇总分析纳入DIAS-3、DIAS-4和DIAS-J三项试验。

主要发现

  • DIAS-4中,去氨普酶组52/124(41.9%)和安慰剂组46/128(35.9%)达到90天mRS 0-2分(OR 1.45,95%CI 0.79-2.64,P=0.23)。
  • DIAS-4两治疗组死亡、症状性颅内出血及其他严重不良事件发生率相等。
  • 汇总分析中,去氨普酶组184/376(48.9%)和安慰剂组171/381(44.9%)达到mRS 0-2分(OR 1.33,95%CI 0.95-1.85,P=0.096)。
  • 去氨普酶提高再通率:107/217(49.3%) vs 85/222(38.3%),OR 1.59,95%CI 1.08-2.35,P=0.019。
  • 再通与两治疗组90天良好结局(mRS 0-2)相关。

关键数值与推荐

  • 主要结局为90天mRS 0-2分。
  • 安全性评估包括死亡率、症状性颅内出血和其他严重不良事件。
  • 去氨普酶剂量为90μg/kg静脉给药。

临床怎么用

  • 对于大动脉闭塞卒中发病3-9小时的患者,去氨普酶可考虑用于提高再通,但需知晓其未显著改善功能结局。
  • 再通与良好功能结局相关,支持血管再通作为治疗目标。

局限性

  • DIAS-4试验因故提前终止,样本量有限。
  • 汇总分析为事后分析,证据等级受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The DIAS-3 trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke [phase 3]) did not demonstrate a significant clinical benefit of desmoteplase administered 3 to 9 hours after stroke in patients with major artery occlusion. We present the results of the prematurely terminated DIAS-4 trial together with a post hoc pooled analysis of the concomitant DIAS-3, DIAS-4, and DIAS-J (Japan) trials to better understand the potential risks and benefits of intravenous desmoteplase for the treatment of ischemic stroke in an extended time window. METHODS: Ischemic stroke patients with occlusion/high-grade stenosis in major cerebral arteries were randomly assigned to intravenous treatment with desmoteplase (90 μg/kg) or placebo. The primary outcome was modified Rankin Scale (mRS) score of 0 to 2 at day 90. Safety assessments included mortality, symptomatic intracranial hemorrhage, and other serious adverse events. RESULTS: In DIAS-4, 52 of 124 (41.9%) desmoteplase-treated and 46 of 128 (35.9%) placebo-treated patients achieved an mRS score of 0 to 2 (odds ratio, 1.45; 95% confidence interval, 0.79; 2.64; P=0.23) with equal mortality, frequency of symptomatic intracranial hemorrhage, and other serious adverse events in both the treatment arms. In the pooled analysis, mRS score of 0 to 2 was achieved by 184 of 376 (48.9%) desmoteplase-treated versus 171 of 381 (44.9%) placebo-treated patients (odds ratio, 1.33; 95% confidence interval, 0.95; 1.85; P=0.096). Treatment with desmoteplase was safe and increased the recanalization rate (107/217 [49.3%] versus 85/222 [38.3%]; odds ratio, 1.59; 95% confidence interval, 1.08-2.35; P=0.019). Recanalization was associated with favorable outcomes (mRS 0-2) at day 90 in both the treatment arms. CONCLUSIONS: Late treatment with intravenous 90 µg/kg desmoteplase is safe, increases arterial recanalization, but does not significantly improve functional outcome at 3 months. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00856661.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. von Kummer R, Mori E, Truelsen T, et al. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke). Stroke. 2016. PMID: 27803391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。